- Home
- EPIX vs CRBP Comparison
EPIX vs CRBP Comparison
Compare EPIX & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPIX
- CRBP
- Stock Information
- Founded
- EPIX 2009
- CRBP 2009
- Country
- EPIX Canada
- CRBP United States
- Employees
- EPIX N/A
- CRBP N/A
- Industry
- EPIX Biotechnology: Pharmaceutical Preparations
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- EPIX Health Care
- CRBP Health Care
- Exchange
- EPIX Nasdaq
- CRBP Nasdaq
- Market Cap
- EPIX 71.5M
- CRBP 73.4M
- IPO Year
- EPIX N/A
- CRBP N/A
- Fundamental
- Price
- EPIX $1.71
- CRBP $7.34
- Analyst Decision
- EPIX Hold
- CRBP Strong Buy
- Analyst Count
- EPIX 3
- CRBP 10
- Target Price
- EPIX $2.00
- CRBP $53.56
- AVG Volume (30 Days)
- EPIX 129.2K
- CRBP 114.6K
- Earning Date
- EPIX 05-08-2025
- CRBP 05-06-2025
- Dividend Yield
- EPIX N/A
- CRBP N/A
- EPS Growth
- EPIX N/A
- CRBP N/A
- EPS
- EPIX N/A
- CRBP N/A
- Revenue
- EPIX N/A
- CRBP N/A
- Revenue This Year
- EPIX N/A
- CRBP N/A
- Revenue Next Year
- EPIX N/A
- CRBP $150.00
- P/E Ratio
- EPIX N/A
- CRBP N/A
- Revenue Growth
- EPIX N/A
- CRBP N/A
- 52 Week Low
- EPIX $1.40
- CRBP $4.64
- 52 Week High
- EPIX $7.88
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- EPIX 53.23
- CRBP 52.51
- Support Level
- EPIX $1.60
- CRBP $7.05
- Resistance Level
- EPIX $1.70
- CRBP $7.62
- Average True Range (ATR)
- EPIX 0.05
- CRBP 0.49
- MACD
- EPIX -0.00
- CRBP -0.02
- Stochastic Oscillator
- EPIX 84.62
- CRBP 42.65
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.